2025 U.S. Most Favored Nation Policy: Implications and Strategic Guidance for Pharma and Biotech
The U.S. pharmaceutical landscape is set for another major shift. On May 12th, President Trump signed a new Executive Order
New 2025 French AP early access program covers nearly 370 innovative treatments
France’s Reimbursed Early Access Programs (EAP) provide opportunities for reimbursement of new and innovative drugs that treat serious diseases before
2025 EU HTA: Launching a New Era in Joint Clinical Assessments
January 12th marked the launch of Joint Clinical Assessment (JCA), a key milestone in the European Union’s Health Technology Assessment
New Technology Add-On Payment (NTAP) 2025 – Key insights
What is NTAP The New Technology Add-On Payment (NTAP) is a reimbursement program under the Centers for Medicare & Medicaid
2025 Market Access Guide for Biotech: What is essential and what is a waste of resources
In the competitive and resource-constrained world of biotechnology, achieving market access and reimbursement is critical. Many biotechs target partnering or
Joint Clinical Assessment (JCA) in the EU: The European Commission adopted the Implementing Act on Joint Clinical Assessment
The implementation of the Joint Clinical Assessment (JCA) in the European Union represents a notable step forward in assessing innovative
